Nanobiotix surges on final talks for cancer therapy development contract

Nanobiotix SA

05/05/2023 11:41

** U.S.-listed shares of Nanobiotix SA  NBTX.O  more than
double to $4.12 premarket    
    ** France-based drug developer says it is entering into
final contract negotiations following a non-binding agreement
for its experimental cancer therapy, NBTXR3, with a "major
global pharmaceutical company"
    ** The non-binding agreement is for development and
commercialization of NBTXR3, which is the co's lead product
candidate and is being tested for treating a type of head and
neck cancer - Nanobiotix
    ** Co adds it does not plan to make additional statements on
contract negotiations until "it is appropriate to do so, or a
final definitive agreement has been signed"
    ** As of last close, U.S.-listed Nanobiotix shares have lost
~45% this year 

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))